Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D)

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2018
This article has no abstract
Epistemonikos ID: 6344a3a0c302bbec69d334d07fa4a5e4857dae3f
First added on: Feb 09, 2025